Reneo Pharmaceuticals Inc (RPHM) Stock
RPHM is no longer traded. Reneo Pharmaceuticals was delisted from the Nasdaq in October 2024.
Prices on this page are historical; the last trade was October 4, 2024 at $1.82.
Reneo Pharmaceuticals stock price history
RPHM final trading statistics
- Final close
- $1.82
- Final trading day
- Oct 4, 2024
- Market cap at delisting
- $60.84M
- Shares outstanding
- 3.34M
- Final 52-week range
- $0.98 – $9.21
- Avg. volume (final 3 mo.)
- 37,868
- All-time high (split-adj.)
- $149.30 · May 2021
- All-time low (split-adj.)
- $0.00 · Apr 2021
- Return since IPO
- +121233.3%
- Beta
- 0.22
- Book value / share
- $23.00
- Price / book
- 0.08
Reneo Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$77.4M | -$2.53 |
| FY2022 | $0.00 | -$50.1M | -$2.12 |
| FY2021 | $0.00 | -$39.8M | -$4.86 |
| FY2020 | $0.00 | -$19.5M | -$0.26 |
| FY2019 | $0.00 | -$12.4M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Reneo Pharmaceuticals Inc
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals stock FAQ
What happened to Reneo Pharmaceuticals stock?
Reneo Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $1.82 on October 4, 2024.
Is RPHM stock still trading?
No. RPHM was delisted from the Nasdaq in October 2024 and no longer trades on a U.S. exchange.
What was the last price of RPHM stock?
RPHM closed at $1.82 on its final trading day, October 4, 2024, for a market value of about $60.84M.
What were Reneo Pharmaceuticals's revenue and earnings in its last full fiscal year?
Reneo Pharmaceuticals reported revenue of $0.00 and net income of -$77.4M in fiscal 2023, its last full year as a public company.
When did Reneo Pharmaceuticals go public?
Reneo Pharmaceuticals Inc stock began trading on April 8, 2021.